96 related articles for article (PubMed ID: 19740505)
21. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
22. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
23. The combined effect of ultrasound exposure and cisplatin on human ovarian carcinoma cells A2780.
Bernard V; Skorpíková J; Mornstein V
Folia Biol (Praha); 2008; 54(3):97-101. PubMed ID: 18647549
[TBL] [Abstract][Full Text] [Related]
24. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
Woods DC; Alvarez C; Johnson AL
Gynecol Oncol; 2008 Mar; 108(3):632-40. PubMed ID: 18191995
[TBL] [Abstract][Full Text] [Related]
26. Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation.
Raaphorst GP; Yang DP; Li LF; Malone S
Anticancer Res; 2004; 24(2B):613-8. PubMed ID: 15161002
[TBL] [Abstract][Full Text] [Related]
27. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
28. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
29. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
31. Effect of treatment schedule on the interaction of Cisplatin and radiation in human lung cancer cells.
Asaka-Amano Y; Takiguchi Y; Yatomi M; Kurosu K; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
Radiat Res; 2007 Jun; 167(6):637-44. PubMed ID: 17523845
[TBL] [Abstract][Full Text] [Related]
32. [Study of ceramide monohexoside in ovarian cell line COC1/DDP resistant to cisplantin].
Qin TN; Wang LL; Chen HG; Gao QH; Zhou RX; Sun BZ; Wang QW
Zhonghua Fu Chan Ke Za Zhi; 2003 Sep; 38(9):556-9. PubMed ID: 14680612
[TBL] [Abstract][Full Text] [Related]
33. Effect of combined treatment with radiation and low dose etoposide on cell survival.
Shigematsu N; Kawata T; Ihara N; Kawaguchi O; Kutsuki S; Ishibashi R; Kubo A; Ito H
Anticancer Res; 2001; 21(1A):325-8. PubMed ID: 11299757
[TBL] [Abstract][Full Text] [Related]
34. The use of models in "target" theory to evaluate the survival curves of human ovarian carcinoma cell line exposure to adriamycin combined with ultrasound.
Yu T; Xiong Z; Chen S; Tu G
Ultrason Sonochem; 2005 Apr; 12(5):345-8. PubMed ID: 15590307
[TBL] [Abstract][Full Text] [Related]
35. Treatment of transplanted adriamycin-resistant ovarian cancers in mice by combination of adriamycin and ultrasound exposure.
Yu T; Huang X; Hu K; Bai J; Wang Z
Ultrason Sonochem; 2004 Jul; 11(5):287-91. PubMed ID: 15157857
[TBL] [Abstract][Full Text] [Related]
36. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
Hamelers IH; Staffhorst RW; Voortman J; de Kruijff B; Reedijk J; van Bergen en Henegouwen PM; de Kroon AI
Clin Cancer Res; 2009 Feb; 15(4):1259-68. PubMed ID: 19228729
[TBL] [Abstract][Full Text] [Related]
37. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
38. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
[TBL] [Abstract][Full Text] [Related]
39. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
Cemazar M; Sersa G; Miklavcic D
Anticancer Res; 1998; 18(6A):4463-6. PubMed ID: 9891510
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
